291 related articles for article (PubMed ID: 30629237)
41. Development of an in vitro cholestatic drug-induced liver injury evaluation system using HepG2-hNTCP-C4 cells in sandwich configuration.
Sakai Y; Okumura H; Iwao T; Watashi K; Ito K; Matsunaga T
Toxicol In Vitro; 2019 Dec; 61():104619. PubMed ID: 31394163
[TBL] [Abstract][Full Text] [Related]
42. Quantitative targeted bile acid profiling as new markers for DILI in a model of methapyrilene-induced liver injury in rats.
Slopianka M; Herrmann A; Pavkovic M; Ellinger-Ziegelbauer H; Ernst R; Mally A; Keck M; Riefke B
Toxicology; 2017 Jul; 386():1-10. PubMed ID: 28529062
[TBL] [Abstract][Full Text] [Related]
43. Ileal bile acid transporter inhibition in Cyp2c70 KO mice ameliorates cholestatic liver injury.
Truong JK; Bennett AL; Klindt C; Donepudi AC; Malla SR; Pachura KJ; Zaufel A; Moustafa T; Dawson PA; Karpen SJ
J Lipid Res; 2022 Sep; 63(9):100261. PubMed ID: 35934110
[TBL] [Abstract][Full Text] [Related]
44. Metabolic Activation of Cholestatic Drug-Induced Bile Acid-Dependent Toxicity in Human Sandwich-Cultured Hepatocytes.
Ogimura E; Tokizono M; Sekine S; Nakagawa T; Bando K; Ito K
J Pharm Sci; 2017 Sep; 106(9):2509-2514. PubMed ID: 28465153
[TBL] [Abstract][Full Text] [Related]
45. Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro.
Woolbright BL; Jaeschke H
Methods Mol Biol; 2015; 1250():363-76. PubMed ID: 26272158
[TBL] [Abstract][Full Text] [Related]
46. Metabolomics research on the hepatoprotective effect of cultured bear bile powder in α-naphthylisothiocyanate-induced cholestatic mice.
Wu J; Fang S; Li W; Li Y; Li Y; Wang T; Yang L; Liu S; Wang Z; Ma Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1153():122269. PubMed ID: 32739790
[TBL] [Abstract][Full Text] [Related]
47. Urinary bile acids as biomarkers for liver diseases II. Signature profiles in patients.
Bathena SP; Thakare R; Gautam N; Mukherjee S; Olivera M; Meza J; Alnouti Y
Toxicol Sci; 2015 Feb; 143(2):308-18. PubMed ID: 25344563
[TBL] [Abstract][Full Text] [Related]
48. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.
Yang K; Köck K; Sedykh A; Tropsha A; Brouwer KL
J Pharm Sci; 2013 Sep; 102(9):3037-57. PubMed ID: 23653385
[TBL] [Abstract][Full Text] [Related]
49. Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides.
Thakare R; Gao H; Kosa RE; Bi YA; Varma MVS; Cerny MA; Sharma R; Kuhn M; Huang B; Liu Y; Yu A; Walker GS; Niosi M; Tremaine L; Alnouti Y; Rodrigues AD
Drug Metab Dispos; 2017 Jul; 45(7):721-733. PubMed ID: 28396527
[TBL] [Abstract][Full Text] [Related]
50. Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes.
Ogimura E; Sekine S; Horie T
Biochem Biophys Res Commun; 2011 Dec; 416(3-4):313-7. PubMed ID: 22108051
[TBL] [Abstract][Full Text] [Related]
51. Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response.
Cai SY; Ouyang X; Chen Y; Soroka CJ; Wang J; Mennone A; Wang Y; Mehal WZ; Jain D; Boyer JL
JCI Insight; 2017 Mar; 2(5):e90780. PubMed ID: 28289714
[TBL] [Abstract][Full Text] [Related]
52. Species differences in bile acids I. Plasma and urine bile acid composition.
Thakare R; Alamoudi JA; Gautam N; Rodrigues AD; Alnouti Y
J Appl Toxicol; 2018 Oct; 38(10):1323-1335. PubMed ID: 29785833
[TBL] [Abstract][Full Text] [Related]
53. Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes.
Kastrinou Lampou V; Poller B; Huth F; Fischer A; Kullak-Ublick GA; Arand M; Schadt HS; Camenisch G
Toxicol In Vitro; 2023 Mar; 87():105533. PubMed ID: 36473578
[TBL] [Abstract][Full Text] [Related]
54. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice.
Song P; Zhang Y; Klaassen CD
Toxicol Sci; 2011 Oct; 123(2):359-67. PubMed ID: 21747115
[TBL] [Abstract][Full Text] [Related]
55. In vitro bile acid-dependent hepatocyte toxicity assay system using human induced pluripotent stem cell-derived hepatocytes: Current status and disadvantages to overcome.
Sakai Y; Iwao T; Susukida T; Nukaga T; Takemura A; Sekine S; Ito K; Matsunaga T
Drug Metab Pharmacokinet; 2019 Aug; 34(4):264-271. PubMed ID: 31285099
[TBL] [Abstract][Full Text] [Related]
56. Bile Acid-Induced Toxicity in HepaRG Cells Recapitulates the Response in Primary Human Hepatocytes.
Woolbright BL; McGill MR; Yan H; Jaeschke H
Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):160-7. PubMed ID: 26176423
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.
Zhang J; He K; Cai L; Chen YC; Yang Y; Shi Q; Woolf TF; Ge W; Guo L; Borlak J; Tong W
Chem Biol Interact; 2016 Aug; 255():45-54. PubMed ID: 27000539
[TBL] [Abstract][Full Text] [Related]
58. Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent.
Parmentier C; Hendriks DFG; Heyd B; Bachellier P; Ingelman-Sundberg M; Richert L
Toxicol Lett; 2018 Oct; 295():187-194. PubMed ID: 29913214
[TBL] [Abstract][Full Text] [Related]
59. Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases.
Yang T; Khan GJ; Wu Z; Wang X; Zhang L; Jiang Z
Drug Discov Today; 2019 Jan; 24(1):112-128. PubMed ID: 30244079
[TBL] [Abstract][Full Text] [Related]
60. Prediction of the Clinical Risk of Drug-Induced Cholestatic Liver Injury Using an In Vitro Sandwich Cultured Hepatocyte Assay.
Susukida T; Sekine S; Nozaki M; Tokizono M; Ito K
Drug Metab Dispos; 2015 Nov; 43(11):1760-8. PubMed ID: 26329788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
